NASDAQ •
Healthcare •
Biotechnology •
Quote as of 08/24/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization558.68 mln
Float51.20 mln
Earnings Date11/18/2026
Piotroski F-Score
3
/ 9
Below average
Relative Strength
91
/ 100
Top performer
Debt / Equity
0.00
Debt-free
ROE
-57.19
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Zura Bio Limited is a clinical-stage company focused on developing treatments for autoimmune and inflammatory diseases. Its lead drug candidate, Tibulizumab, is currently in Phase 2 trials and works by blocking two key proteins involved in these conditions within a single molecule. The company also has two other drug candidates, Torudokimab and Crebankitug, each targeting different proteins linked to inflammation, both of which have completed early-stage clinical testing. Founded in 2022 and based in Henderson, Nevada, Zura Bio is building a focused portfolio aimed at addressing serious immune-related conditions.
